Updated Survival Data for Ipilimumab to be Presented
PRINCETON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX) announced today that nine clinical abstracts for ipilimumab,
an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be
the subject of presentations at the 33rd Congress of the European Society
for Medical Oncology (ESMO) being held September 12-16, 2008 in Stockholm.
Many of the following abstracts will include updated one-year survival data
from three Phase 2 studies (008, 022 and 007) in previously treated
patients with advanced metastatic melanoma:
Ipilimumab Presentations in Advanced Melanoma
-- "Efficacy and safety of patients with advanced melanoma treated with
ipilimumab with or without the addition of prophylactic budesonide"
(Abstract #783P) I. Ron - Poster presentation from 12:45 p.m. to 1:45 p.m.
local time on Saturday, September 13, 2008.
-- "Treatment guidelines for the management of immune-related adverse
events in patients treated with ipilimumab, an anti-CTLA4 therapy"
(Abstract #787P) K. Chin - Poster discussion from 12:45 p.m. to 1:45 p.m.
local time on Saturday, September 13, 2008.
-- "Ipilimumab-mediated patterns of response in patients with
pretreated, advanced melanoma" (Abstract #784P) K. Harmankaya - Poster
presentation from 12:45 p.m. to 1:45 p.m. local time on Saturday, September
13, 2008.
-- "Clinical activity of ipilimumab in patients with advanced melanoma
and brain metastases" (Abstract #786P) J. S. Weber - Poster presentation
from 12:45 p.m. to 1:45 p.m. local time on Saturday, September 13, 2008.
-- "Ipilimumab 10 mg/kg induction dosing promotes T-cell activation in
patients with advanced melanoma" (Abstract #785P) A. Hoos - Poster
presentation and discussion from 12:45 p.m. to 1:45 p.m. local time on
Saturday, September 13, 2008.
-- "Effect of dose on efficacy and safety in ipilimumab-treated
patients with advanced melanoma - results from a Phase 2, randomized,
dose-ranging study" (Abstract #769O) C. Lebbe - Oral presentation from 3:30
p.m. to 5:30 p.m. local time on Monday, September 15, 2008.
-- "Efficacy and safety of treatment-naive and previously treated
patients with advanced melanoma receiving ipilimumab" (Abstract #778PD) R.
Ridolfi - Poster discussion from 12:30 p.m. to 1:30 p.m. local time on
Monday, September 15, 2008.
-- "Efficacy and safety of ipilimumab in patients with advanced
melanoma who had progressed on one or more prior therapies: results from a
single-arm, multicenter study" (Abstract #776PD) M. Maio - Poster
discussion from 12:30 p.m. to 1:30 p.m. local time on Monday, September 15,
2008.
-- "Prolonged stable disease in ipilimumab-treated patients with
advanced melanoma who have progressed on prior anticancer therapies"
(Abstract #768O) V. Chiarion Sileni - Oral presentation from 3:30 p.m. to
5:30 p.m. local time on Monday, September 15, 2008.
More information about the ESMO Congress may be found at http://www.esmo.org.
About Medarex
Medarex is a biopharmaceutical company focused on the discovery,
development and potential commercialization of fully human antibody-based
therapeutics to treat life-threatening and debilitating diseases, including
cancer, inflammation, autoimmune disorders and infectious diseases. Medarex
applies its UltiMAb(R) technology and product development and clinical
manufacturing experience to generate, support and potentially commercialize
a broad range of fully human antibody product candidates for itself and its
partners. More than 40 of these therapeutic product candidates derived from
Medarex technology are in human clinical testing or have had INDs submitted
for such trials, with seven of the most advanced product candidates
currently in Phase 3 clinical trials or the subject of regulatory
applications for marketing authorization. Medarex is committed to building
value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit
its website at http://www.medarex.com.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks
of Medarex, Inc. All rights are reserved.
SOURCE Medarex, Inc.
 back to top
Related links:
http://www.medarex.com
http://www.esmo.org
http://www.prnewswire.com/comp/108265.html /
CONTACT:
Laura S. Choi, Investor Relations,
+1-609-430-2880, x2216; or Nichol Harber, Corporate
Communications (media), +1-609-430-2880, x2214, both of Medarex,
Inc.
|
